Evidence map›Paper›PMID 26425084›Full record

ArticleInternational journal of nanomedicine2015

Preparation and characterization of anti-HIV nanodrug targeted to microfold cell of gut-associated lymphoid tissue.

Upal Roy, Hong Ding, Sudheesh Pilakka-Kanthikeel, Andrea D Raymond, Venkata Atluri, Adriana Yndart, Elena M Kaftanovskaya, Elena Batrakova, Marisela Agudelo, Madhavan Nair

Open access · goldAbstract read
In one paragraph

Article in International journal of nanomedicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 32 citations in OpenAlex.

  1. Article
  2. Histochemistry for Molecular Imaging in Nanomedicine.International journal of molecular sciences · 2024
    Review
  3. Delivering CRISPR to the HIV-1 reservoirs.Frontiers in microbiology · 2024
    Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Upal RoyCenter for Personalized NanoMedicine, Institute of NeuroImmune Pharmacology, Department of Immunology, Florida International University, Miami, FL, USA.
Hong DingCenter for Personalized NanoMedicine, Institute of NeuroImmune Pharmacology, Department of Immunology, Florida International University, Miami, FL, USA.
Sudheesh Pilakka-KanthikeelCenter for Personalized NanoMedicine, Institute of NeuroImmune Pharmacology, Department of Immunology, Florida International University, Miami, FL, USA.
Andrea D RaymondCenter for Personalized NanoMedicine, Institute of NeuroImmune Pharmacology, Department of Immunology, Florida International University, Miami, FL, USA.
Venkata AtluriCenter for Personalized NanoMedicine, Institute of NeuroImmune Pharmacology, Department of Immunology, Florida International University, Miami, FL, USA.
Adriana YndartCenter for Personalized NanoMedicine, Institute of NeuroImmune Pharmacology, Department of Immunology, Florida International University, Miami, FL, USA.
Elena M KaftanovskayaDepartment of Human and Molecular Genetics, Herbert Wertheim College of Medicine, Florida International University, Miami, FL, USA.
Elena BatrakovaUNC Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Marisela AgudeloCenter for Personalized NanoMedicine, Institute of NeuroImmune Pharmacology, Department of Immunology, Florida International University, Miami, FL, USA.
Madhavan NairCenter for Personalized NanoMedicine, Institute of NeuroImmune Pharmacology, Department of Immunology, Florida International University, Miami, FL, USA.
Florida International University · USUniversity of North Carolina at Chapel Hill · US

Funding

Polydrug Nanocarrier to Treat Opiate Addiction and HIV DiseaseR01DA027049 · NIDA · FLORIDA INTERNATIONAL UNIVERSITY · PI NAIR, MADHAVAN P. · 2009 to 2014
$3.1M
Cocaine in the Neuropathogenesis of HIV infection: Role of HDAC2R01DA034547 · NIDA · FLORIDA INTERNATIONAL UNIVERSITY · PI NAIR, MADHAVAN P. · 2013 to 2018
$1.8M
Multifunctional Nanocarrier to Eradicate HIV from latently infected CNS cells andR01DA037838 · NIDA · FLORIDA INTERNATIONAL UNIVERSITY · PI NAIR, MADHAVAN P. · 2014 to 2018
$1.8M
Novel Magneto-Electric Nanodelivery of Drugs to Eradicate HIV from CNSR21MH101025 · NIMH · FLORIDA INTERNATIONAL UNIVERSITY · PI NAIR, MADHAVAN P. · 2013 to 2014
$388k
NIDA NIH HHS 1R01DA027049NIDA NIH HHS 1R01DA037838-01NIDA NIH HHS R01 DA027049NIDA NIH HHS R01 DA034547NIDA NIH HHS R01DA034547-01NIDA NIH HHS R01 DA037838NIMH NIH HHS 1R21MH101025NIMH NIH HHS R21 MH101025
6 · The paper itself

Abstract

The human immunodeficiency virus 1 (HIV-1) still remains one of the leading life-threatening diseases in the world. The introduction of highly active antiretroviral therapy has significantly reduced disease morbidity and mortality. However, most of the drugs have variable penetrance into viral reservoir sites, including gut-associated lymphoid tissue (GALT). Being the largest lymphoid organ, GALT plays a key role in early HIV infection and host-pathogen interaction. Many different treatment options have been proposed to eradicate the virus from GALT. However, it becomes difficult to deliver traditional drugs to the GALT because of its complex physiology. In this regard, we developed a polymer-based Pluronic nanocarrier containing anti-HIV drug called efavirenz (EFV) targeting Microfold cells (M-cells) in the GALT. M-cells are specialized epithelial cells that are predominantly present in the GALT. In this work, we have exploited this paracellular transport property of M-cells for targeted delivery of Pluronic nanocarrier tagged EFV, bioconjugated with anti-M-cell-specific antibodies to the GALT (nanodrug). Preliminary characterization showed that the nanodrug (EFV-F12-COOH) is of 140 nm size with 0.3 polydispersion index, and the zeta potential of the particles was -19.38±2.2 mV. Further, drug dissolution study has shown a significantly improved sustained release over free drugs. Binding potential of nanodrug with M-cell was also confirmed with fluorescence microscopy and in vitro uptake and release studies. The anti-HIV activity of the nanodrug was also significantly higher compared to that of free drug. This novel formulation was able to show sustained release of EFV and inhibit the HIV-1 infection in the GALT compared to the free drug. The present study has potential for our in vivo targeted nanodrug delivery system by combining traditional enteric-coated capsule technique via oral administration.

Indexed as

Drug Delivery SystemsAnti-HIV AgentsCaco-2 CellsCell ProliferationCells, CulturedFlow CytometryFluorescent Antibody TechniqueGastrointestinal TractHIV-1HIV InfectionsHumansLymph NodesMacrophagesNanoparticlesReactive Oxygen SpeciesAnti-HIV AgentsReactive Oxygen Speciesdrug deliveryGALTHIV-1M-cells

Identifiers

PMID26425084
PMCPMC4583111
OpenAlexW1424782268

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.